Introduction
The dystrophin gene encodes a 427 kDa cytoskeletal muscle protein that is a key protein for healthy musculoskeletal function. Dystrophin preserves the integrity of the muscle sarcolemma by providing a critical link from filamentous actin in the cytoplasm of muscle cells to the extracellular matrix, and by anchoring other muscle proteins adjacent to the cytoplasmic face of the sarcolemma. The absence of dystrophin results in muscle degeneration and necrosis, causing muscle weakness manifested in the disease, Duchenne muscular dystrophy (DMD). 1, 2 Duchenne muscular dystrophy, an X-linked, recessive, fatal disease due to dystrophin gene mutation, affects 1:3500 live male births and is the most common form of muscular dystrophy. 1 The disease presents clinically during childhood, but the disease can be diagnosed before birth by fetal muscle biopsy or molecular analysis of DNA from chorionic villi or amniotic fluid cells. [3] [4] [5] [6] Normal muscle fibers have approximately uniform size with nuclei located at the periphery, whereas dystrophic muscle shows signs of degeneration and regeneration manifested by muscle fibers of varying sizes and with centrally placed nuclei. 7, 8 Over time, this degenerative process leads to infiltration and replacement of muscle fibers with connective tissue and ultimately results in loss of function and death. Gene transfer of a normal dystrophin cDNA provides the potential of treatment, since the replacement of a single gene is necessary to correct the disease state.
A widely-used model for DMD gene therapy research, the mdx mouse, was discovered as a mutant strain of C57BL/10-ScSn mice with higher than normal levels of serum creatine kinase. 9 A single nucleotide change in the dystrophin gene of this C57BL/10 background strain generated a nonsense mutation and therefore, the absence of full-length dystrophin protein in skeletal and cardiac muscle, providing a genetic and biochemical model of human DMD. 2, 10 Previous studies have demonstrated a force deficit in mdx muscle studied in vitro as well.
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A high-capacity adenoviral (HC-Ad) vector carrying the full-length murine dystrophin cDNA was used for in utero gene delivery to mdx mice in this study. 12 The HC-Ad vector can carry a large expression cassette (up to approximately 30 kb of insert capacity) and lacks all viral genes. Therefore, the vector can deliver a full-length dystrophin cDNA and confers lower induction of immunity compared to first-generation Ad vectors. 13, 14 Previous transgenic studies suggest that provision of a full-length dystrophin protein would be optimally therapeutic compared to an in-frame truncated dystrophin protein that can be provided by the first-generation Ad vector or the adeno-associated viral vector (AAV). 15 The intramuscular vector injections for this study were administered at embryonic gestation day 16 (E-16) , the stage at which secondary myotubes are forming in fetal muscle tissue. 16 Prenatal treatment offers many possible advantages over postnatal treatment, including delivery of vector at the earliest point in the disease process and prior to the full development of the immune system. The availability of routine prenatal diagnostic testing for DMD facilitates the potential for fetal treatment. [3] [4] [5] [6] Ad vector muscle gene transfer to adult animals has many drawbacks including increased immunogenicity and low transduction efficiency. Previous studies have shown a downregulation of the primary Ad receptor, the coxsackie and adenovirus receptor with muscle maturation, leading to low transduction efficiency. 17 Therefore, gene transfer to the fetus may be more desirable as fetal tissue has a high level of coxsackie and adenovirus receptor expression. 18 Also, gene delivery prior to the activation of proinflammatory pathways, such as those signaling through NF-kB, will be important as these pathways have been shown by mRNA profiling studies to be active soon after birth in dystrophin-deficient muscle. 19 Another potential advantage of prenatal treatment is the opportunity to use smaller doses of vector. Finally, in utero gene delivery offers the possibility of tolerance to the vector and/or transgene product. A previous study demonstrated the development of tolerance to the factor IX transgene product delivered by an Ad vector in utero.
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Our goal for this study was to test whether HC-Ad vector gene transfer to a mouse disease model of DMD could lead to effective gene replacement and improved muscle function. We treated E-16 mdx mice in utero with a single intramuscular hindlimb injection of a HC-Ad vector carrying the full-length murine dystrophin cDNA.
Recombinant dystrophin expression, restoration of the dystrophin-glycoprotein complex (DGC), morphological effects and in vitro muscle force production were analyzed. These results extend previous in utero gene delivery experiments with marker genes to an application of gene delivery in a DMD disease model using an HC-Ad vector carrying the full-length dystrophin gene.
Results

Distribution of dystrophin expression in hindlimb
At 9 weeks of age, following in utero intramuscular injection, all muscles of experimental animals in this study were analyzed by immunohistochemistry (tibialis anterior, gastrocnemius and quadriceps). Recombinant dystrophin expression from AdmDys, a HC-Ad vector carrying a full-length murine dystrophin cassette driven by the muscle specific MCK (muscle creatine kinase) promoter, was correctly localized to the cytoplasmic face of the sarcolemma in transduced mdx hindlimb muscles ( Figure 1 ). Furthermore, by viewing longitudinal and serial cross-sections, we observed dystrophin expression from AdmDys along the entire longitudinal extent of individual muscle fibers.
The majority of animals had recombinant dystrophin expression in two muscles of the injected hindlimb (Table 1) . Although the three doses of vector used in this study were relatively close (Table 1) , the higher-dose group showed slightly higher levels of expression by immunohistochemistry. The levels of dystrophin expression were too low to be detected by western blot (data not shown). Serial staining for dystrophin-associated proteins a-and b-sarcoglycan demonstrates that in utero treatment with AdmDys conferred restoration of the 
In vitro force production and muscle mass
To determine functional benefit from in utero intramuscular treatment of mdx mice with AdmDys, we analyzed specific tetanic force production and muscle mass of tibialis anterior muscles. Six animals demonstrated recombinant dystrophin expression in the tibialis anterior muscle (Table 1 ), but functional data are shown for only five animals ( Figure 2 ), as one mouse, 3C (Table 1) , was sick and could not be analyzed. C57BL/10 normal control mice showed significantly higher specific force production from the tibialis anterior muscle than mdx dystrophic control mice (P ¼ 0.000), mdx treated (P ¼ 0.033) and mdx contralateral legs (P ¼ 0.000). The treated tibialis anterior muscle of the injected mice revealed an increase in specific tetanic force production compared to the contralateral leg and mdx controls; however, the difference did not reach statistical significance ( Figure 2a ). Mdx control mice (P ¼ 0.000) and mdx contralateral legs (P ¼ 0.0128) had significantly higher tibialis anterior muscle mass (reflecting a hypertrophic response to muscle degeneration) than their C57BL/10 counterparts (P ¼ 0.000; Figure 2b ). Treated animals had a significantly lower tibialis anterior muscle mass in their treated leg as compared to their contralateral leg (P ¼ 0.0431) and mdx controls (P ¼ 0.0093). Also, there was no significant difference between C57BL/10 controls and treated mdx tibialis anterior muscles (P ¼ 0.2938). Interestingly, treated animals with lower muscle mass in the injected hindlimb also had lower muscle mass in their untreated contralateral hindlimb, when compared to age-matched mdx, although it was not significant (P ¼ 0.0532; Figure 2b ).
Frequency of centralized nuclei as a function of recombinant dystrophin expression
Since the majority of mice (8/11) demonstrated dystrophin expression in the gastrocnemius muscle of the injected hindlimb, we used this muscle for morphological analysis to correlate dystrophin expression with centrally placed nuclei, a characteristic histological finding indicating previous muscle fiber degeneration and regeneration. The average dystrophin expression in transduced gastrocnemius muscles was 25.1±13.4 dystrophin (+) fibers per cross-section, with each section having approximately 500-600 muscle fibers. The percentage of dystrophin-expressing muscle fibers harboring centrally placed nuclei was 16.6±11.1%, whereas the percentage of muscle fibers lacking dystrophin expression that had centrally placed nuclei was 90.7±4.0%. These data demonstrate that muscle fibers expressing recombinant dystrophin from in utero treatment with AdmDys were effectively protected from cycles of degeneration. 
Abbreviations: Gas, gastrocnemius; gc, genome copies; Quad, quadriceps; TA, tibialis anterior; (+), detectable expression; (À), no detectable expression. C57BL/10 n = 23 * * * * * Figure 2 Force production and muscle mass of tibialis anterior muscles expressing recombinant dystrophin. For functional analysis, the TA muscles collected from experimental mice at 9 weeks of age were analyzed in vitro. Age-matched C57BL/10 and mdx control mice were studied concurrently as positive and negative controls, respectively. The number of animals studied (n) is indicated. Specific tetanic force (a) and the ratio of TA muscle mass to total mouse body mass (b) is shown for treated and contralateral TA muscles from the five animals displaying recombinant dystrophin expression in the treated TA muscle, with each point representing a single hindlimb muscle. *C57BL/10 specific tetanic force is significantly different from mdx control, treated and contralateral hindlimb (Po0.05). **C57BL/10 ratio of TA to total body mass is significantly different from mdx control and contralateral hindlimb (Po0.05). ***mdx-treated hindlimb is significantly different from mdx control and contralateral hindlimb (Po0.05). TA, tibialis anterior.
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Discussion
Muscle degradation due to the absence of dystrophin and the DGC results in severe, progressive and irreversible muscle weakness in DMD patients. 1 Previous postnatal gene transfer studies in animal models of DMD have shown that localization of recombinant dystrophin to the muscle membrane of dystrophic muscle fibers by introduction of a dystrophin transgene restored the DGC in those fibers. 21 Our results show that the localization of recombinant dystrophin to the muscle membrane expressed from AdmDys delivered by a single in utero injection to mdx mouse muscle restored the DGC in muscles studied postnatally. In contrast to postnatal muscle gene transfer studies using Ad vectors, where the distribution of gene transduction is limited largely to the injection site in a single muscle, [22] [23] [24] we observed transduction of 2-3 muscles of an injected hindlimb when gene delivery was performed in utero. We speculate that this reflects greater vector spread in fetal muscles, since the mass of muscle is small, basal lamina and other connective tissue structures are not fully formed 25 and the volume of the injectate is large relative to the volume of tissue.
Ultimately, gene delivery therapy for DMD needs to provide preservation of muscle strength. We observed a trend toward increased force production and showed significantly decreased muscle mass, two findings that suggest a functional benefit of the in utero-delivered dystrophin transgene despite the low number of fibers transduced. Interestingly, treated animals also had a lower muscle mass in the untreated, contralateral hindlimb, although this trend did not quite reach significance. It is difficult to definitively conclude whether this finding in the untreated limb is due, in part, to the aspects of surgical manipulation. It is unlikely to be a systemic therapeutic effect, although this possibility cannot be definitively excluded. Functional studies in HC-Ad-dystrophin vector gene transfer experiments were only performed previously in neonatal and adult mdx mice. 24, 26, 27 A comparison with these studies suggests that much higher levels of dystrophin expression would be required to see more dramatic evidence of functional benefit following in utero dystrophin gene delivery.
We, and others, have performed in utero intramuscular delivery using Ad, AAV and lentiviral vector systems. Previous studies using first-generation Ad and AAV vectors show expression after in utero gene therapy persisting as long as 86 weeks from an Ad vector and up to 58 weeks from an AAV vector, with expression in skeletal and cardiac muscle and low levels of neutralizing antibodies. 28 Using AAV1 and AAV2 intramuscular injections in utero, we have previously shown high levels of marker gene expression predominantly in multiple muscle groups of the injected hindlimb, with lower levels seen in other organs based on the serotype. 29 Intramuscular in utero studies using lentiviral vectors with different pseudotypes revealed transduction of satellite cells capable of regenerating muscle fibers, 30 and an earlier study showed expression in the injected hindlimb and the cardiac muscle at various time points after injection. 31 In addition, studies using targeted lentiviral vectors show promising results from integrating vector systems with expression noted up to 15 months after a single in utero injection. 32 While previous studies have shown key aspects of in utero gene transfer to muscle, our study provides attempted treatment of a biochemical mouse model for human DMD with a vector carrying a full-length dystrophin cDNA, which cannot be done using first-generation Ad, AAV or lentiviral vectors.
We utilized an HC-Ad vector with the full-length murine dystrophin cDNA under control of a 6.5 kb MCK promoter including the first intron. The MCK promoter provides the benefit of muscle specific expression; however, the level of transgene expression driven by the MCK promoter is lower than that with the ubiquitously expressing human cytomegalovirus promoter. 33 Previous in utero HC-Ad vector muscle transduction studies using a lacZ vector have shown that the human cytomegalovirus promoter provides high levels of b-gal expression in injected hindlimb muscles of C57BL/6 mice at 1 and 5 months after a single in utero muscle injection. 34 Also, for this current study, the vector titer became a limiting factor, since a maximum volume of 5 ml could be injected into the fetal hindlimb. Furthermore, since the Ad vector does not integrate into the host genome, there is a potential for vector dilution by muscle growth between E-16 and 9 weeks of age as we have previously shown in the marker gene studies. 34 In mdx mice, the ongoing degeneration and regeneration of dystrophin-deficient muscle fibers results in an increasing percentage of fibers harboring centrally placed nuclei. In previous studies, treatment of postnatal pups prior to the first morphological evidence of muscle degeneration (approximately 2 weeks of age), resulted in a protective effect as indicated by a low level of centrally placed nuclei in dystrophin (+) fibers. 23 We observed a similar protective effect in mice transduced during the fetal stage in this study.
Despite encouraging effects on morphology and restoration of the DGC, our results suggest that a critical component of successful in utero dystrophin gene delivery will be the achievement of higher levels of muscle transduction, likely requiring advances beyond current technology.
Materials and methods
Adenoviral vector
The HC-Ad vector, AdmDys, contains the viral left and right inverted terminal repeats of adenovirus serotype 5, HPRT (hypoxanthine-guanine phosphoribosyltransferase) 'stuffer' DNA and a full-length 13.8 kb murine dystrophin cDNA/pA under the control of the 6.5 kb MCK promoter. The vector construction was fully described previously. 12 Mice and in utero administration of the adenoviral vector
In utero intramuscular injections of AdmDys were administered on approximately four E-16 fetuses, each of timed-pregnant adult mdx female mice. Only a subset of fetuses (approximately four per pregnant dam) can be injected in utero without increasing the rate of fetal loss. Only one mother in this study died after surgery and prior to delivery. Six treated animals available for analysis had been injected in the hindlimb with either 4.5 Â 10 7 or 5.2 Â 10 7 gc pup À1 of AdmDys in 5 ml
Dystrophin transfer in utero DP Reay et al volumes as described previously. 18 We subsequently enhanced our treated pup identification procedure by giving an injection of 2% orange fluorescent FluoSpheres (Invitrogen, Carlsbad, CA, USA) at the same time as gene transfer. Treated pups were identified by ultraviolet light screening after natural birth. Using this identification technique, five additional animals were studied after AdmDys administration of 4 Â 10 7 gc pup À1 . Treated animals were analyzed at 9 weeks of age in comparison to age-matched mdx and C57BL/10 controls.
In vitro functional analysis of tibialis anterior muscles
Functional analysis was performed on both tibialis anterior muscles 9 weeks after birth following in utero AdmDys administration. In vitro functional analysis included specific tetanic force production and mass of tibialis anterior muscles of C57BL/10, mdx control and treated mdx mice, as described previously. 35 The investigator performing in vitro functional testing was blinded to treatment. Specific force and tibialis anterior muscle mass-ratio statistical analyses were performed with STATA se8 (Stata Corporation, College Station, TX, USA). Analysis of variance with Scheffe's post hoc test for multiple comparisons was used to identify differences between groups with respect to specific force. The Kruskall-Wallis test was used to identify overall differences with respect to tibialis anterior muscle mass ratios. Signrank or ranksum tests were used to identify differences among pairs, where applicable.
Detection of dystrophin, a-sarcoglycan and b-sarcoglycan
Muscles were snap frozen and fully sectioned to observe the extent of dystrophin expression. Immunostaining for dystrophin, a-sarcoglycan and b-sarcoglycan of serial muscle sections was done. 34, 36 C57BL/10 normal muscle served as a positive control, while uninjected mdx and contralateral hindlimb muscles of injected animals provided negative controls.
Detection of nucleus position within muscle fibers
To visualize dystrophin and the position of nuclei within muscle fibers in injected hindlimb muscles by bright field microscopy, muscle sections were immunostained for dystrophin and counterstained with hematoxylin. Muscle sections were incubated with NCL-DYS2 (Novacastra Laboratories Ltd; Newcastle upon Tyne, UK) primary antibody, at a dilution of 1:20. A sheep anti-mouse IgG conjugated to peroxidase (Amersham Biosciences; Piscataway, NJ, USA) was used as the secondary antibody at a dilution of 1:100, followed by incubation of muscle sections with 3,3 0 diaminobenzidine tetrahydrochloride peroxidase substrate, according to the manufacturer's instructions (DAB Substrate Kit for peroxidase; Vector Laboratories; Burlingame, CA, USA). The staining was enhanced using diaminobenzidine tetrahydrochloride enhancement solution, according to the manufacturer's instructions (Vector Laboratories), prior to hematoxylin counterstaining. Serial muscle sections were also stained with hematoxylin and eosin. The transduced gastrocnemius muscles from all mice demonstrating dystrophin expression were analyzed to score all dystrophin (+) fibers and regions of approximately 200 dystrophin (À) fibers in the same muscle for centralized nuclei to yield percentages of dystrophin (+) and dystrophin (À) fibers harboring centralized nuclei.
